Generic Targretin Now Available in US
The first generic version of Valeant's bexarotene (Targretin) is now available from Mylan.
The first generic version of Valeant’s bexarotene (Targretin) is now available from Mylan.
The retinoid is indicated to treat cutaneous manifestations of t-cell lymphoma in patients who are refractory to at least 1 prior systemic treatment.
“Mylan's launch of the first and only generic Targretin is another example of our commitment to expand access to high quality, more affordable medicines,” Mylan CEO Heather Bresch stated. “…We look forward to continue meeting patient, payer, and provider needs in this space."
Targretin had US sales of approximately $155 million for 1 year ending on March 31, 2015, according to IMS Health data.
Some of the drug’s most common side effects include headache, weakness, tiredness, and increased sensitivity to cold. Serious adverse effects may include sudden stomach or back pain, severe nausea, and fever.
